The company's stock value has tanked before - it was once worth $1 billion.

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, top-performing sectors, and what’s next for biotech investors.

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in ...

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Kraig Biocraft Laboratories (OTCQB:KBLB) deployed one million genetically engineered silkworm eggs across multiple ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many ...

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

A California-based biotech company announced it will be cutting roughly half of its workforce after a disappointing study result saw its stock plummet. Gossamer Bio confirmed to KRON4.com that it ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.